Quoin Pharmaceuticals, Ltd. (QNRX): Nasdaq/NYSE listing notice — Quoin Pharma receives Nasdaq notice for non-compliance with $1.00 minimum bid price

Quoin Pharmaceuticals, Ltd.

Received Nasdaq notice on April 29, 2024 for failing to maintain minimum bid price of $1.00 per ADS for 31 consecutive business days through April 26, 2024.
No immediate effect on listing; ADSs continue trading on Nasdaq Capital Market under symbol QNRX.
Company has 180 calendar days, until October 28, 2024, to regain compliance by having closing bid price >= $1.00 for at least 10 consecutive business days.
If not compliant by October 28, may be eligible for a second 180-day period if it meets other initial listing standards.
Company will monitor bid price and consider available options to cure the deficiency.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Quoin Pharmaceuticals, Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

April 29, 2024, Quoin Pharmaceuticals Ltd. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 31 consecutive business days (March 14, 2024 through April 26, 2024), the Company’s American Depositary Shares (“ADSs”) did not maintain a minimum closing bid price of $1.00 (“Minimum Bid Price Requirement”) per ADS as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s ADSs and the ADSs will continue to trade on Th

View on SEC.gov

99 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Quoin Pharmaceuticals, Ltd. filing history →

Source: SEC EDGAR

accession 0001104659-24-057008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.